Summary of Key Points Core Viewpoint - The report details the fundraising activities and the usage of raised funds by Shandong LianKe Technology Co., Ltd., highlighting the amounts raised, their allocation, and the current status of these funds as of March 31, 2025 [1][2]. Fundraising Overview - The total net amount raised from the initial public offering (IPO) was RMB 596,312,839.61 after deducting issuance costs of RMB 52,972,160.39 [2]. - The company was also approved to raise RMB 265,472,460.69 through a simplified procedure for a specific audience, with all funds received by June 27, 2023 [2]. Fund Usage and Balance - The net amount from the IPO was allocated as follows: - Pre-investment project replacement: RMB 160,118,544.89 - Post-investment project replacement: RMB 169,401,612.76 - Bank loan repayment: RMB 120,000,000.00 - Working capital: RMB 124,972,046.07 - Total interest income: RMB 14,990,416.15 - Remaining balance as of March 31, 2025: RMB 36,811,052.04 [2][3]. - For the funds raised through the simplified procedure, the allocations were: - Pre-investment project replacement: RMB 42,882,174.99 - Post-investment project replacement: RMB 205,344,603.35 - Total interest income: RMB 6,662,477.79 - Remaining balance as of March 31, 2025: RMB 23,908,160.14 [2][3]. Fund Management - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, including the storage of funds in dedicated bank accounts under a tripartite supervision agreement [4][5]. Investment Project Status - There were no changes or transfers in the investment projects funded by the raised capital [6]. - The actual investment amounts for various projects differed from the committed amounts, with reasons provided for discrepancies, such as ongoing construction or market conditions affecting project timelines [8][9]. Project Benefits and Performance - The report includes a table detailing the benefits realized from the investment projects, with some projects unable to be individually assessed for profitability due to their nature [9][10]. - The "10,000 tons/year high-dispersed silica project" and the "10,000 tons/year high-pressure cable shielding material project" are highlighted, with the latter expected to generate significant profits once fully operational [10][11]. Idle Funds - The company has not utilized idle funds for purposes other than those specified in the fundraising commitments [11].

Core Viewpoint - The company has completed the convertible bond fundraising project and plans to permanently supplement its working capital with the remaining funds of 60,787,077.87 yuan, which includes cash management income and interest [1][4][6]. Summary by Sections Fundraising Project Completion - The company held a board meeting on July 3, 2025, to approve the conclusion of the convertible bond fundraising project, which has reached its intended operational status [1][7]. - The total amount raised through the convertible bonds was 285 million yuan, with a net amount of 279.79889 million yuan after deducting issuance costs [2][4]. Fund Management and Usage - A special account was established for the management of the raised funds, and a tripartite supervision agreement was signed with relevant parties [3][5]. - As of July 3, 2025, the remaining funds in the special account amounted to 60,787,077.87 yuan, representing 21.73% of the total raised funds [4][5]. Reasons for Fund Surplus - The surplus funds resulted from careful resource allocation and cost control during the project, as well as reduced material and funding needs due to a decline in factory order volumes [5][6]. - The company also achieved cash management income from idle funds, enhancing the efficiency of fund usage [5][6]. Future Use of Surplus Funds - The company intends to use the surplus funds to permanently supplement its working capital, which will support ongoing and future business operations [6][7]. - The decision to use the surplus funds does not alter the intended use of the raised funds and complies with relevant regulations [6][7]. Approval Process - The board's audit committee reviewed and approved the proposal to conclude the fundraising project and use the surplus funds, which will be submitted for shareholder approval [6][7][8].

三生国健: 三生国健：关于公司2024年度募集资金存放与实际使用情况的专项 报告 证券代码：688336 证券简称：三生国健 公告编号：2025-012 三生国健药业（上海）股份有限公司 关于公司 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、《上海证券交易所科创板上市公司自律监管指引第 关规定，三生国健药业（上海）股份有限公司（以下简称"公司"或 "本公司"）董事会对 2024 年度募集资金存放与实际使用情况专项 报告说明如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账时间 公司经上海证券交易所科创板股票上市委员会 2020 年 5 月 11 日 审核同意，并经中国证券监督管理委员会 2020 年 6 月 23 日《关于同 意三生国健药业（上海）股份有限公司首次公开发行股票注册的批复》 （证监许可20201217 号）注册同意，首次公开发行人民币普通股 （A 股）股票 61,6 ...